267344US0PC Docket No.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Takayuki FURUISHI, et al. IN RE APPLICATION OF:

SERIAL NO: New U.S. PCT Application Based on PCT/JP03/I1420

GAU:

Herewith FILED:

EXAMINER:

FOR-

PROLINE ESTER AND PREPARATION CONTAINING THE SAME FOR PERCUTANEOUS

ADMINISTRATION

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Registration No. 24,618

Customer Number

22850 Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Surinder Sachar Registration No. 34,423

							ET 1		1
				ATTY DOCKET NO.		SERIA	(a) / 5	270	16
orm PTO 1449 - U.S. DEPARTMENT OF COMMERC PATENT AND TRADEMARK OFFICE			F COMMERCE EMARK OFFICE	267344US0PCT	SERIALING / 5 27 0 6 New U.S. PCT Application Based on PCT/JP03/11420				
				APPLICANT					
LIST OF	REFERE	ENCES CITED BY APP	PLICANT	Takayuki FURUISHI, et al.					
			FILING DATE	GROUP					
				Herewith	L				
				U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	IF AP	PROPRIA	TE
	AA					-			
	AB				+				
	AC				+	-			
	AD				+				
	AE								
	AF						—		
	AG				+				
	AH AI								
	AJ								
	AK								
	AL								
	AM								
	AN								
			F	OREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO)
	AO								
	AP								
	AQ								
	AR		<u> </u>			-			
	AS					+	-		
	AT		 						
	AU								
	AV				D	ata \			
		OTHER R	EFERENCE	S (Including Author, Title, Date, Pertine	ent Pages,	etc.)	The Dha	maceutics	al .
	AW	Society of Japan Ner	ikai Koen Yo	at Yudotai no Keihi Kyushu-sei ni Kansun shishu, No. 4, page 106, March 2003.					
	AX	OF THEIR PRODRU	GS. Noven P	ISDERMAL ADMINISTRATION OF ACE harmaceuticals, Inc., AAPS Annual Meet m/NovenDoc3.pdf.> g to the Configuration and Conformation	ing and Ex	posicilon,	2000 a		
	AY	FISCHER J. et al., S Liebigs Annalen der	tudies Relatir Chemie 1989	g to the Configuration and Conformation, No.11, pages 1093 to 1097.	01 3, 3-DIS			- (21.) 1016	
	AZ				□ A4	ditional R	eferences	sheet(s) a	attache
Examiner					Date Considered				
*Cuaminar	Initial if	reference is considered	d, whether or	not citation is in conformance with MPER orm with next communication to applican	609; Drav	v line throu	gh citation	n if not in	
conformant	ce and r	ioi considered, include	COPY OF BIRS I	on the next communication to applican					